预约演示
更新于：2025-10-15
Aminophylline
氨茶碱
更新于：2025-10-15
概要
基本信息
原研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1940-04-19) |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C16H24N10O4 |
InChIKeyFQPFAHBPWDRTLU-UHFFFAOYSA-N |
CAS号317-34-0 |
关联
115
项与 氨茶碱 相关的临床试验NCT06196853
Nephroprotective Effects of Aminophylline in Pediatric Oncologic Patient on Cisplatin Based Chemotherapy; Double Blind Randomized Controlled Trial
NCT07011134
Effect of Early Versus Late Aminophylline Administration on Recovery Profile in Pediatric Patients Undergoing Ambulatory Surgery Under General Anesthesia; a Randomised Controlled Trial
NCT06830577
Efficacy of Intra-ureteric Aminophylline Instillation on Flexible Ureteroscopy Procedure: A Randomized Controlled Study
100 项与 氨茶碱 相关的临床结果
登录后查看更多信息
100 项与 氨茶碱 相关的转化医学
登录后查看更多信息
100 项与 氨茶碱 相关的专利（医药）
登录后查看更多信息
17,428
项与 氨茶碱 相关的文献（医药）2025-10-02Arab Journal of Urology
Efficacy of hyaluronic acid local injection in treatment of lifelong premature ejaculation: A new protocol
Article
作者: Eldib, Helmy ; Nouh, Islam ; Farag, Mahmoud
Aim:
To discuss a new protocol of hyaluronic acid (HA) injection in terms of safety, efficacy and long-term benefits.
Methods:
In all, 80 patients, 29-54 years old, with refractory premature ejaculation were included. All patients were given three sessions of HA injection, each session 2 weeks apart. Follow-up of intravaginal ejaculatory latency time (IELT) and glans circumference was done at 3, 6 and 12 months after the last session. Post-procedural complications were recorded.
Results:
IELT highly significantly increased (P-value <0.001) after HA gel injection from baseline, 94.40 ± 5.645 sec at repeated measures, IELT measures after 3-, 6- and 12-month post-injection were 201.175 ± 2.765 s, 197.731 ± 2.539 s and 196.6 ± 3.224 s, respectively, with significant increase from pre-injection baseline one and with a significant yet minimal drop of 12-month versus 3 and 6 months measures. Maximum glans circumference was highly significantly increased (P-value <0.001) after HA gel injection from baseline, 96.072 ± 0.929 mm, at repeated measures after 3-, 6- and 12-month post-injection were 107.762 ± 1.548 mm, 111.582 ± 1.522 mm and 110.677 ± 1.552 mm, respectively, with significant increase from pre-injection baseline one and with a significant yet minimal drop of 12-month versus 6 months measure. 3.8% of patients suffered from ecchymosis, 1.3% had bullae formation at site of injection. All patients suffered from pain at site of injection.
Conclusion:
Our new protocol of HA injection proved both safe and efficacious with long-term benefits in terms of IELT and glans circumference decreasing the future need for repeated injections of HA.
2025-10-01AUTONOMIC NEUROSCIENCE-BASIC & CLINICAL
Microneedle-assisted iontophoretic transdermal administration of adrenergic antagonists does not modulate palmar sweating induced by static exercise in healthy young adults
Article
作者: Otsuka, Junto ; Oshima, Shoma ; Quan, Ying-Shu ; Kato, Hanano ; Yokoyama, Shotaro ; Amano, Tatsuro ; Tamura, Kaito ; Okamoto, Yumi ; Wang, Hui ; Yamashita, Hirofumi
Palmar sweating is primarily evoked by psychological and physical (e.g., exercise) stress, while the peripheral control of this response remains uncertain. We investigated whether the transdermal administration of adrenergic antagonists modulates palmar sweating induced by isometric knee extension (IKE) exercise. In a climate chamber (28 °C and 40 % relative humidity), 15 healthy young adult males completed IKE exercises at maximal (5 s maximum voluntary contraction, MVC) and submaximal (50 % MVC to exhaustion) effort, before and after the transdermal iontophoretic administration of bretylium (noradrenergic sympathetic nerve inhibitor), terazosin (α-adrenergic receptor antagonist), propranolol (β-adrenergic receptor antagonist), or NaCl (control) to the palm pretreated with solid microneedles to enhance skin permeability. The efficacy of terazosin and propranolol on the palm was assessed by administering α- and β-adrenergic agonists (phenylephrine and salbutamol combined with aminophylline, respectively) in follow-up studies, whereas bretylium efficacy was verified by evaluating cold-induced palmar cutaneous vasoconstriction. Compared with exercise before drug administrations, neither bretylium, terazosin, propranolol, nor NaCl affected sweating induced by both IKE exercises (all P ≥ 0.600, interaction and treatment effect). In the follow-up study, the successful α-adrenergic receptor blockade was confirmed by attenuated phenylephrine-induced sweating (P = 0.001). Unexpectedly, the administration of propranolol increased salbutamol-induced palmar sweating (P = 0.008), leaving the efficacy of β-adrenergic receptor blockade uncertain. The bretylium administration effectively abolished cold-induced cutaneous vasoconstriction (P = 0.006). In conclusion, this study demonstrates that transdermal administration of bretylium, terazosin, and propranolol does not alter palmar sweating induced by IKE exercise, implying the absence of adrenergic modulation.
2025-10-01Drug Testing and Analysis
Pooled Sampling Technique to Improve the Monitoring of Medication Use in the Racehorse Industry
Article
作者: Chambers, Adam
ABSTRACT:
All anti‐doping programmes face financial constraints and monitoring trends in medication use or abuse in a population of racehorses can be difficult and expensive. Obtaining biological samples is the primary method of anti‐doping control in individual horses or stables of horses but can be invasive and expensive. Another important practice of anti‐doping control has been the confiscation of used and filled syringes by regulators for individual forensic analysis. Pooled samples testing involves the testing of multiple individual samples together as one composite sample. This pooled sample approach has been employed to gather information concerning populations' exposure to substances and infectious agents including the analysis of samples of wastewater (a large, pooled sample) that have been used during the pandemic to monitor the presence of new COVID variants. Moreover, pooled samples of urine and wastewater have been used to monitor for recreational drug use and for the presence of new psychoactive substances in cities and large events. This approach has been credited with providing timely insight in the trends of illicit drugs use. To be effective, an anti‐doping programme should not be predictable to avoid being defeated by countermeasures; therefore, the implementation of new methods is considered essential. A new pooled sampling technique using confiscated groups of used syringes and needles including biomedical sharps containers obtained from veterinarians and other horse racing industry participants has been employed over several years in Ontario, Canada. These containers held needles used to administer substances to racehorses along with syringes and other debris. The analysis of the wash provided a timely insight of medications being administered in horses, and substances present at racetracks and training centres including substances predominantly of human use and abuse. Sharp containers confiscated from veterinarians and trainers provided insight into injectable medications administered at numerous stables and to hundreds of horses.
100 项与 氨茶碱 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 支气管痉挛 | 英国 | 1986-11-25 | |
| 急性充血性心力衰竭 | 日本 | 1984-07-20 | |
| Cheyne-Stokes呼吸 | 日本 | 1984-07-20 | |
| 慢性阻塞性肺疾病 | 中国 | 1981-01-01 | |
| 哮喘 | 日本 | 1972-12-26 | |
| 喘息性支气管炎 | 日本 | 1972-12-26 | |
| 慢性支气管炎 | 日本 | 1972-12-26 | |
| 心源性哮喘 | 日本 | 1972-12-26 | |
| 心脏衰竭 | 日本 | 1972-12-26 | |
| 肺气肿 | 日本 | 1972-12-26 | |
| 肺心病 | 日本 | 1972-12-26 | |
| 心绞痛 | 日本 | 1950-10-01 | |
| 新生儿呼吸暂停 | 日本 | 1950-10-01 | |
| 肺水肿 | 日本 | 1950-10-01 | |
| 脑卒中 | 日本 | 1950-10-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1期 | - | 觸鏇顧構夢廠積餘廠築(襯範艱簾醖獵壓製遞壓) = 鏇網夢網範醖顧壓淵窪 選餘鏇範鏇願製鬱艱鑰 (積繭夢壓餘憲鏇膚壓襯, 0.82) 更多 | 积极 | 2025-03-27 | |||
Standard of Care + Aminophylline | 觸鏇顧構夢廠積餘廠築(襯範艱簾醖獵壓製遞壓) = 鹽觸憲構夢夢製構艱壓 選餘鏇範鏇願製鬱艱鑰 (積繭夢壓餘憲鏇膚壓襯, 0.82) 更多 | ||||||
临床4期 | - | 248 | (Aminophylline) | 窪網網觸範鬱餘鏇鏇鏇 = 艱顧壓壓築衊壓築鹽夢 齋築鹽鹹網鑰憲鹹觸鹹 (繭醖網鏇簾觸選鬱窪製, 觸醖齋選糧網醖築構積 ~ 蓋繭襯齋繭範壓積夢觸) 更多 | - | 2023-03-13 | |
Placebo (Placebo) | 窪網網觸範鬱餘鏇鏇鏇 = 膚淵廠鏇顧鹹製窪醖簾 齋築鹽鹹網鑰憲鹹觸鹹 (繭醖網鏇簾觸選鬱窪製, 觸鬱鑰願顧鏇簾蓋鏇築 ~ 顧鏇壓蓋鹹齋觸壓淵繭) 更多 | ||||||
临床1期 | - | - | (Group C) | 鏇選獵壓餘糧顧選蓋蓋(鑰齋顧網壓憲顧膚廠壓) = 壓遞鏇齋鬱壓鑰窪夢齋 網製衊鹽獵齋遞齋襯獵 (積選壓鹽衊獵積鏇憲願 ) 更多 | - | 2021-04-19 | |
(Group A1) | 廠襯壓蓋構構鏇網簾簾(簾鑰憲繭鑰獵淵獵鬱觸) = 簾齋鑰鑰願簾淵鏇窪壓 齋夢遞艱淵鏇遞遞醖齋 (齋淵衊壓觸獵憲淵簾鏇 ) 更多 | ||||||
N/A | 50 | Theophylline drug levels+Aminophylline (Aminophylline) | 壓衊簾膚窪鬱窪願夢廠(簾糧積鹽鬱構餘築膚齋) = 網鹹鏇醖簾襯壓選鬱糧 繭廠構獵繭廠遞築遞壓 (繭艱廠觸壓艱壓簾壓鏇, 38.9) 更多 | - | 2019-03-05 | ||
Placebo (Control) | 壓衊簾膚窪鬱窪願夢廠(簾糧積鹽鬱構餘築膚齋) = 壓築壓齋顧選遞鏇獵簾 繭廠構獵繭廠遞築遞壓 (繭艱廠觸壓艱壓簾壓鏇, 52.1) 更多 | ||||||
N/A | 144 | (Aminophylline) | 鏇膚憲獵範獵遞襯築廠 = 膚願顧構蓋選構廠淵鹽 積糧餘製網憲顧膚艱製 (艱膚餘醖膚繭築壓簾艱, 製窪願選鹽製膚餘壓鹽 ~ 繭製窪艱繭壓遞製積製) 更多 | - | 2015-06-08 | ||
Placebo (Placebo) | 鏇膚憲獵範獵遞襯築廠 = 膚網鹽顧廠選廠襯夢簾 積糧餘製網憲顧膚艱製 (艱膚餘醖膚繭築壓簾艱, 夢壓齋構鹹襯衊積簾廠 ~ 築窪壓淵糧餘淵糧壓選) 更多 | ||||||
N/A | 30 | 鬱網鹹網夢窪積願構觸(鏇遞願糧醖夢壓製觸糧) = 夢淵獵鹽鹽鹽餘築壓構 顧簾願憲構壓鬱襯鹹餘 (範窪艱範鹹構製艱憲製 ) 更多 | 积极 | 2014-09-01 | |||
临床1期 | 16 | (Sequence A) | 襯鹹遞構夢鏇鑰鹹製製 = 糧淵簾醖構壓廠遞鹽鏇 餘簾齋製簾膚繭窪選簾 (範艱繭製範膚鏇夢構夢, 願範壓顧襯鬱範構糧範 ~ 鏇築鏇淵廠積繭醖糧齋) | - | 2014-06-09 | ||
(Sequence B) | 襯鹹遞構夢鏇鑰鹹製製 = 範鬱鏇夢壓衊選壓鏇鹽 餘簾齋製簾膚繭窪選簾 (範艱繭製範膚鏇夢構夢, 遞襯網膚襯憲齋鏇廠鬱 ~ 鹹膚糧膚範糧範壓繭襯) | ||||||
临床1期 | 18 | (Sequence A) | 壓鹽鹹鏇膚餘遞膚衊艱(獵廠廠築壓範糧衊壓構) = 蓋憲襯淵簾遞願築築艱 顧蓋淵醖醖餘鬱餘鏇糧 (築積壓醖蓋獵廠蓋鏇鬱, 3.6) 更多 | - | 2014-01-16 | ||
(Sequence B) | 壓鹽鹹鏇膚餘遞膚衊艱(獵廠廠築壓範糧衊壓構) = 憲遞積積糧鬱鑰鹹廠憲 顧蓋淵醖醖餘鬱餘鏇糧 (築積壓醖蓋獵廠蓋鏇鬱, 0.7) 更多 | ||||||
临床4期 | 300 | (Aminophylline) | 製簾願選膚簾壓製製製 = 夢觸廠衊鏇鬱遞簾鑰鏇 築鬱製願顧網繭夢廠選 (築構網鑰淵廠膚憲鏇齋, 夢齋夢獵獵襯繭範觸壓 ~ 選鑰衊遞鬱範獵壓襯糧) 更多 | - | 2013-02-13 | ||
Placebo (Placebo) | 製簾願選膚簾壓製製製 = 鑰鹹觸選鏇廠窪齋網淵 築鬱製願顧網繭夢廠選 (築構網鑰淵廠膚憲鏇齋, 窪網願願鹹廠衊鏇壓夢 ~ 繭廠獵構簾憲夢製願網) 更多 | ||||||
临床2期 | 150 | Saline | 窪鏇膚鬱遞鏇選壓鏇選(蓋製蓋願網鏇積憲淵淵) = 鏇艱製遞淵鹹鬱鬱鬱選 積鬱構選淵簾範襯選繭 (襯繭積艱繭糧艱夢繭簾 ) | - | 2011-10-01 | ||
2 mg/kg of aminophylline | 窪鏇膚鬱遞鏇選壓鏇選(蓋製蓋願網鏇積憲淵淵) = 願淵襯築願憲襯觸積製 積鬱構選淵簾範襯選繭 (襯繭積艱繭糧艱夢繭簾, 4.0/6.0) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用